While Pradaxa was suffering, Xarelto was increased by 103%... why it that?

What has happened in the year?

It is known that the prescription expense ranking for the next generation new oral anticoagulant (NOAC) was changed last year. According to the UBIST, a company finding the total of outpatient prescription expenses, it was observed that the Bayer Healthcare’s ‘Xarelto (generic name: rivaroxaban)’ took the 1^st over the BoehringerIngelheim’s‘Pradaxa (generic name: ...